The PMMR Framework for Lorlatinib Adverse Events

Adverse events on lorlatinib are not a question of if, but when. The PMMR framework (Prepare, Monitor, Manage, Reassess) gives community oncology teams a repeatable structure for handling them without losing disease control.

Written by Katrina Metz, RT·Medically reviewed by Dr. Geoffrey Liu, MD MPH·Last updated

Key Takeaways

  • Adverse events on lorlatinib should be anticipated and planned for, not reacted to.
  • The conversation that matters most happens before the first dose, not after the first side effect.
  • Early monitoring should combine lab work and patient report, with the focus shifting as treatment continues.
  • Problems managed early rarely accumulate. Problems that are ignored tend to stack up.
  • PMMR is a continuous cycle, not a one-time checklist.

Table of Contents

Why a Framework Is Needed

Lorlatinib delivers durable disease control in ALK-positive non-small cell lung cancer. The clinical challenge is rarely efficacy. It is keeping the patient on therapy long enough to benefit from it.

Adverse events on lorlatinib are common, and most are Grade 1 or 2. What separates a patient who stays on treatment for years from one who discontinues early is usually not the severity of any single event. It is whether the team had a structure for catching it and responding proportionally.

The Four Steps

Prepare

Set expectations before the first dose. Different adverse events appear at different times, some in the first two weeks and others months in. Patients who understand that timeline are far less likely to be alarmed or to stop reporting.

Two things need to be established in that first conversation: what to expect, and how to report it. Early reporting is the single strongest predictor of successful management.

Key message: Have the discussion before the first dose.

Monitor

Monitoring combines two streams: laboratory values such as the lipid panel, and patient report such as concentration and mood.

The balance between them shifts over time. Early on, metabolic labs carry the most signal, because that is where changes appear first. Assess both clinically and biochemically within the first month, then stay relatively close through the following three months.

Key message: Early on, focus on metabolic labs. Assess clinically and biochemically within the first month, then stay close for three months.

Manage

Respond in proportion to what you find. The options run from supportive care through to dose reduction, and most events are handled well before the dose needs to change.

Key message: Problems managed early rarely accumulate. Problems that are ignored tend to stack up.

Reassess

After every intervention, ask whether it worked. Is daily function maintained or improved? Have new issues appeared?

Key message: PMMR is not a one-time checklist. It is a continuous cycle.

What This Looks Like in Practice

When the framework is applied consistently, patients stay on therapy, maintain quality of life, and benefit from the full potential of treatment.

Frequently Asked Questions

What is the PMMR framework?
PMMR stands for Prepare, Monitor, Manage, Reassess. It is a practical framework for managing lorlatinib's adverse effects, developed by Dr. Geoffrey Liu and colleagues and published in Lung Cancer (2024). Prepare means setting expectations with the patient before the first dose. Monitor combines laboratory values and patient report. Manage means responding in proportion to functional impact. Reassess means confirming the intervention worked and checking for new issues. It is a continuous cycle rather than a one-time checklist. Related: Video 1: PMMR and the Foundations of ALK+ Patient Management
What is the recommended starting dose of lorlatinib?
The recommended starting dose is 100 mg daily. Clinical guidance is to begin at full dose unless contraindicated. Early adverse events are common but often manageable, and starting at full dose maximises initial disease control. Related: Video 8: Dosing and Dose Modification Strategies
Does reducing the dose of lorlatinib compromise its effectiveness?
No. Dose reduction in the early weeks did not compromise progression-free survival or intracranial outcomes. Structured reductions go from 100 mg to 75 mg daily, and to 50 mg daily if a second reduction is required. Dose reduction is part of long-term management, not treatment failure, and this should be stated explicitly to patients. Related: Video 8: Dosing and Dose Modification Strategies
How often should lipids be monitored on lorlatinib?
A baseline lipid profile, a recheck at one month, two months and then every 3 months. Onset of lipid changes is approximately 15 days, which is why the two-week check matters. Trend over time is more informative than any single value. Related: Video 7: Hyperlipidemia and Metabolic Effects
Which statins are preferred in patients on lorlatinib?
Pitavastatin, pravastatin and rosuvastatin are preferred, selected on the basis of their drug interaction profile. If control is inadequate, ezetimibe can be added, and a fibrate or fish oil for triglycerides. Diet alone is rarely sufficient, and dose reduction of lorlatinib is rarely required for lipids alone. Related: Video 7: Hyperlipidemia and Metabolic Effects
How common are adverse events on lorlatinib?
Most adverse events are Grade 1 or 2. Hypercholesterolemia occurs in approximately 70 to 75 percent of patients and hypertriglyceridemia in approximately 60 to 65 percent. Weight gain occurred in approximately 44 percent of patients in long-term CROWN follow-up. Peripheral edema, peripheral neuropathy and CNS effects are also common, with median onset of two to four months. For most events, incidence does not increase over time. These are CROWN long-term follow-up figures rather than a global average. Related: Video 2: Weight Gain · Video 3: Peripheral Edema · Video 4: Peripheral Neuropathy
What CNS side effects can occur with lorlatinib, and are they reversible?
CNS adverse events include changes in mood, cognition and speech. Most are Grade 1 to 2, with median onset at two to four months, and discontinuation rates are very low. These changes are often early and reversible with structured intervention. The main clinical risk is delayed recognition rather than the severity of the event, which is why caregiver input is valuable. Changes are frequently noticed by a family member before the patient reports them. Related: Video 5: Cognitive and Mood Changes
Should therapy be switched if there is isolated CNS progression?
Not automatically. If progression is intracranial only, confirm the imaging, assess symptom burden, consider local therapy, and continue CNS-active systemic therapy where appropriate. Time to intracranial progression is significantly prolonged with lorlatinib, and dose reduction does not compromise intracranial efficacy. Therapy should not be switched reflexively for limited CNS progression. Related: Video 9: Sequencing After Progression · Video 6: Brain Metastasis
When should a patient on lorlatinib be referred to a specialist?
Refer when function, safety, or disease control is at risk. Neurology or psychiatry for functional cognitive impairment, behavioral instability, safety concerns, or persistent CNS toxicity despite dose adjustment. Cardiology or a lipid clinic when lipids remain uncontrolled despite maximal statin therapy, or where there is statin intolerance or complex cardiovascular risk. Radiation oncology or a tertiary centre for isolated CNS progression or symptomatic lesions. Central oncologic oversight should be maintained throughout. Related: Video 11: When to Refer to a Specialist
How often should patients on lorlatinib be followed up?
Biweekly during the first month, monthly for three months, and every three months thereafter. After any treatment interruption, return to biweekly reassessment. A standardised adverse event checklist at each visit, screening for weight change, edema, neuropathy, and mood or cognition, improves detection compared with open-ended questioning. Related: Video 10: Clinical Tools for Monitoring and Follow-Up

This content is intended for healthcare professional education and reflects clinical guidance current at the time of publication. It is not a substitute for the product monograph, institutional protocols, or individual clinical judgement.

Stay Informed

RESPIPLUS publishes free, evidence-based education for Canadian healthcare professionals across chronic lung diseases, including new videos, clinical guides and podcast episodes, with no paywall and no cost.

Subscribe to RESPIPLUS updates →

This video is one of twelve in Managing Lorlatinib in ALK+ NSCLC, developed with Dr. Geoffrey Liu and the CARMA-BROS network at Princess Margaret Cancer Centre.

Watch the full series →  ·  Explore the Lung Cancer Hub →

Continue the Series

Related Resources

About this article

Written by Katrina Metz, RT, respiratory therapist and medical writer at RESPIPLUS. Medically reviewed by Dr. Geoffrey Liu, MD MPH, Senior Scientist at Princess Margaret Cancer Centre and a leading Canadian expert in ALK-positive NSCLC management.

About this project
This series was supported by Pfizer and developed independently by RESPIPLUS with the CARMA-BROS network. Scientific Committee: Dr. Geoffrey Liu (Princess Margaret), Maria Sedeno (RESPIPLUS), Emily Horvat (RESPIPLUS), Katrina Metz (RESPIPLUS), Christopher Deutschman (CARMA-BROS), Faisal Al Agha (CARMA-BROS). All materials are free and permanently hosted on chroniclungdiseases.com.

Published August 4, 2026. Last reviewed . For educational purposes only. Not a substitute for medical advice.